Week of May 3rd, 2021 | Vol. 10, Issue 19 |
|
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events
Quick Links
Contact Information
Managing Director
Business Development
Managing Director
Head of M&A and Capital Advisory
|
|
Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.
|
|
For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.
|
|
MARKET REPORTS
Recent Materials Providing Insight Into Healthcare Related Industries
|
|
Current M&A Pipeline
Representative Current Retained Sell-Side And Partnering Opportunities
|
|
Project Focus
Sell-side | CMO | Liquids and Semi-solids CMO headquartered in Canada
Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics
Project Aspen
Sell-side | CDMO | Multinational CDMO headquartered in US
Project Athena
Sell-side / Licensing | Medical Device | Novel device for pelvic organ prolapse
|
|
Albany Molecular Research, Inc. (AMRI), a global provider of contract research, development and manufacturing services, expanded access to its accelerated solutions platform, spanning R&D to manufacturing for orphan and rare disease products. The company made targeted investments globally to expand its scale and compound handling capabilities and made additions to the teams that address the specific needs of these complex products in its facilities in Albany, NY, Grafton, WI, and Glasgow, Scotland.
The expansion includes additional GMP suites in Albany designed to manufacture batch sizes of 10-15 kilograms, which is critical for the production of rare-disease therapies. AMRI’s Grafton facility has expanded its hydrogenation, filtering and drying and analytical capabilities and added liquid chromatography-mass spectrometry and gas chromatography-mass spectrometry instruments, and recruited additional analytical experts. AMRI’s Glasgow facility is an integrated single site with formulation development and clinical sterile drug product manufacture capabilities, which supports formulation and process development and GMP manufacture of orphan drug products.
|
|
RECENT INDUSTRY TRANSACTIONS
An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
|
|
Pharma & Biotech
10 transactions totaling $443 million
Supplies, Equipment & Services
30 transactions totaling $845 million
Healthcare IT & Managed Care
7 transactions totaling $74 million
Healthcare Facilities & Distributors
6 transactions totaling $6,025 million
|
|
Pharma & Biotech
39 transactions totaling $1,341 million
Supplies, Equipment & Services
31 transactions totaling $476 million
Healthcare IT & Managed Care
21 transactions totaling $647 million
Healthcare Facilities & Distributors
2 transactions totaling $14 million
|
|
Pharma & Biotech
18 transactions totaling $1,347 million
Supplies, Equipment & Services
6 transactions totaling $342 million
Healthcare IT & Managed Care
0 transactions
Healthcare Facilities & Distributors
0 transactions
|
|
INDUSTRY TRADING COMPS
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
|
|
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.
For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table.
Note: data reflects prior week close.
|
|
|
RECENT INDUSTRY TRANSACTIONS
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
|
|
April 30, 2021 - Fierce Pharma
Pfizer will begin shipping doses of its BioNTech-partnered vaccine to Canada beginning next week, making it the second country to receive U.S.-made doses of the drugmakers' vaccine. Some EU member states are pushing the bloc to strike a supply agreement with Valneva for its inactivated vaccine candidate despite recent setbacks in negotiations, sources tell Reuters.
April 29, 2021 - Fierce Healthcare
Humana will purchase the remaining stake from TPG Capital. The insurer currently has a 40% ownership stake in Kindred, valued at $2.4 billion. The insurer said buying out the remaining interest in Kindred will allow it to more quickly scale up its plans to launch value-based care models and innovative care.
April 28, 2021 - Fierce Biotech
Amplyx received investment from Pfizer last year as part of a $93 million series C round that set the biotech up to advance fosmanogepix and MAU868, a neutralizing antibody targeting the BK virus. In the months after disclosing the investment, Amplyx shared phase 2 data linking fosmanogepix to an 80% treatment success rate in patients with invasive fungal infections caused by Candida.
April 28, 2021 - Contract Pharma
The expansion enhances PPD’s ability to deliver global scientific and technical expertise to meet growing customer demand in Europe, the Middle East and Africa, and the Asia-Pacific region. By offering these services at its Athlone operation, PPD can provide clients in these locations with the same services already available in the U.S. through its Middleton, WI, GMP lab.
|
|
Welcome to Bourne, let's talk.
Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.
|
|
|
|
|
|
|
